Monopar to Present at the 35th Annual Roth Conference

Rhea-AI Summary

Monopar Therapeutics (Nasdaq: MNPR), a biopharmaceutical company dedicated to cancer therapeutics, announced that CEO Chandler Robinson will participate in a fireside chat at the 35th Annual Roth Conference.

Event Details:
Date: March 13, 2023
Time: 12:30-1:00 pm PT
Location: The Ritz Carlton, Laguna Niguel, Dana Point, California.

Monopar's pipeline includes Validive® (Phase 2b/3) for severe oral mucositis, camsirubicin (Phase 1b) for soft tissue sarcoma, and MNPR-101 & MNPR-202 for advanced cancers. For more information, visit www.monopartx.com.

WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat at the 35^th Annual Roth Conference.

Presentation Details:

Date: March 13, 2023
Time: 12:30-1:00 pm Pacific Time
Location: The Ritz Carlton, Laguna Niguel in Dana Point, California

https://www.roth.com/conferences/upcoming-conferences

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® (Phase 2b/3) for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:  

Monopar Therapeutics Inc.
Investor Relations  
Kim R. Tsuchimoto  
Chief Financial Officer  
kimtsu@monopartx.com

Follow Monopar on social media for updates: 
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

FAQ

What is Monopar Therapeutics participating in on March 13, 2023?

Monopar Therapeutics is participating in a fireside chat at the 35th Annual Roth Conference.

Who will represent Monopar Therapeutics at the Roth Conference?

CEO Chandler Robinson will represent Monopar Therapeutics at the Roth Conference.

Where is the 35th Annual Roth Conference being held?

The conference is being held at The Ritz Carlton, Laguna Niguel in Dana Point, California.

What time is Monopar's presentation at the Roth Conference?

Monopar's presentation is scheduled for 12:30-1:00 pm Pacific Time.

What is Monopar Therapeutics focused on developing?

Monopar Therapeutics focuses on therapeutics designed to improve the quality of life for cancer patients.